Nippon Kayaku acquires Asian rights to Spectrum's bladder cancer drug
This article was originally published in Scrip
Executive Summary
The Japanese oncology specialist Nippon Kayaku has acquired Asian rights to Spectrum Pharmaceuticals' bladder cancer product apaziquone, for $15 million upfront and up to $136 million in regulatory and commercial milestones.